BSF’s Kerato Secures Québec-Backed Grant to Drive LiQD Cornea Veterinary Trials and North American Launch

BSF Enterprise PLC ( (GB:BSFA) ) has issued an update.

Kerato Limited, the corneal-focused biotechnology subsidiary of BSF Enterprise PLC, has secured participation as an industrial partner in a CAD 663,000 PSO V2D grant programme awarded by Québec’s Ministry of Economy, Innovation and Energy to the University of Montreal, with Kerato co-funding about 55% of the 18‑month project. The funding will support safety and biocompatibility testing, veterinary clinical trials of its LiQD Cornea Animal Health product, manufacturing scale-up, quality and regulatory readiness, and intellectual property work, all aimed at de-risking both veterinary and future human applications. Veterinary trials are due to start in Q1 2026, with a targeted initial commercial launch of LiQD Cornea Animal Health in Canada in Q1 2027 and first revenues expected thereafter, while early engagement with Health Canada and collaboration with the University of Montreal and Axelys are intended to strengthen Kerato’s North American presence and accelerate access to high-value veterinary and clinical markets, ultimately supporting the longer-term development of human corneal repair solutions.

The most recent analyst rating on (GB:BSFA) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on BSF Enterprise PLC stock, see the GB:BSFA Stock Forecast page.

Spark’s Take on GB:BSFA Stock

According to Spark, TipRanks’ AI Analyst, GB:BSFA is a Neutral.

The stock’s overall score is driven by strong technical momentum, despite weak financial performance and valuation concerns. The lack of profitability and negative cash flows are significant risks, but positive price trends provide some optimism.

To see Spark’s full report on GB:BSFA stock, click here.

More about BSF Enterprise PLC

BSF Enterprise PLC is a UK-based company that develops and commercialises tissue-engineered products, including lab-grown leather, cultivated meat and corneal repair technologies, using a proprietary scaffold-free platform to provide sustainable alternatives to traditional materials and meet growing demand for environmentally responsible innovations. Its wholly owned subsidiary, Kerato Limited, focuses on tissue-engineered corneal solutions for veterinary and human health, led by its first product, LiQD Cornea, a drop-applied regenerative device designed to repair corneal damage and address unmet clinical needs and donor shortages.

Average Trading Volume: 1,298,585

Technical Sentiment Signal: Hold

Current Market Cap: £3.53M

See more insights into BSFA stock on TipRanks’ Stock Analysis page.